Scientists have pinpointed thousands of genetic changes in a gene that may increase a person's risk of developing breast and ovarian cancer, paving the way for better risk assessment and more personalised care.
A blood test that uses artificial intelligence (AI) to detect cancer-related genetic changes and protein biomarkers could help screen women for early signs of ovarian cancer, according to a study by researchers at the Johns Hopkins Kimmel Cancer Center in collaboration with several other institutions in the United States and Europe.
This new article publication from Acta Pharmaceutica Sinica B, discusses how molecular glue triggers degradation of PHGDH by enhancing the interaction between DDB1 and PHGDH.
AB ANALITICA partners in DECIDER project to improve diagnostics and treatment of ovarian cancer with the help of AI – 15 million euros in funding from the EU
An ultrasound test that detected 96% of ovarian cancers in postmenopausal women should replace current standard of care test in the UK according to a new study.
Researchers developed a groundbreaking method to detect ovarian cancer early by analyzing cfDNA fragmentomes and protein biomarkers, significantly improving sensitivity and specificity over existing approaches.
In a recent study, researchers used high-throughput drug screening to identify potential therapeutic targets and novel treatments for low-grade serous ovarian cancer (LGSOC), offering hope for more effective and personalized therapies.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
